These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Loss of heterozygosity on chromosome 13 is common only in the biologically more aggressive subtypes of ovarian epithelial tumors and is associated with normal retinoblastoma gene expression. Kim TM; Benedict WF; Xu HJ; Hu SX; Gosewehr J; Velicescu M; Yin E; Zheng J; D'Ablaing G; Dubeau L Cancer Res; 1994 Feb; 54(3):605-9. PubMed ID: 8306317 [TBL] [Abstract][Full Text] [Related]
3. Differences in p16 gene methylation and expression in benign and malignant ovarian tumors. McCluskey LL; Chen C; Delgadillo E; Felix JC; Muderspach LI; Dubeau L Gynecol Oncol; 1999 Jan; 72(1):87-92. PubMed ID: 9889036 [TBL] [Abstract][Full Text] [Related]
4. Retinoblastoma protein expression in endometrial hyperplasia and carcinoma. Niemann TH; Yilmaz AG; McGaughy VR; Vaccarello L Gynecol Oncol; 1997 May; 65(2):232-6. PubMed ID: 9159330 [TBL] [Abstract][Full Text] [Related]
5. Evidence of functional RB protein in epithelial ovarian carcinomas despite loss of heterozygosity at the RB locus. Dodson MK; Cliby WA; Xu HJ; DeLacey KA; Hu SX; Keeney GL; Li J; Podratz KC; Jenkins RB; Benedict WF Cancer Res; 1994 Feb; 54(3):610-3. PubMed ID: 8306318 [TBL] [Abstract][Full Text] [Related]
6. Frequent down-regulation and lack of mutation of the KAI1 metastasis suppressor gene in epithelial ovarian carcinoma. Liu FS; Dong JT; Chen JT; Hsieh YT; Ho ES; Hung MJ Gynecol Oncol; 2000 Jul; 78(1):10-5. PubMed ID: 10873402 [TBL] [Abstract][Full Text] [Related]
7. Decreased luteinizing hormone receptor mRNA expression in human ovarian epithelial cancer. Lu JJ; Zheng Y; Kang X; Yuan JM; Lauchlan SC; Pike MC; Zheng W Gynecol Oncol; 2000 Nov; 79(2):158-68. PubMed ID: 11063638 [TBL] [Abstract][Full Text] [Related]
8. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. Schmandt RE; Broaddus R; Lu KH; Shvartsman H; Thornton A; Malpica A; Sun C; Bodurka DC; Gershenson DM Cancer; 2003 Aug; 98(4):758-64. PubMed ID: 12910520 [TBL] [Abstract][Full Text] [Related]
9. Expression of survivin is associated with malignant potential in epithelial ovarian carcinoma. Takai N; Miyazaki T; Nishida M; Nasu K; Miyakawa I Int J Mol Med; 2002 Aug; 10(2):211-6. PubMed ID: 12119561 [TBL] [Abstract][Full Text] [Related]
10. Promoter hypermethylation profile of ovarian epithelial neoplasms. Makarla PB; Saboorian MH; Ashfaq R; Toyooka KO; Toyooka S; Minna JD; Gazdar AF; Schorge JO Clin Cancer Res; 2005 Aug; 11(15):5365-9. PubMed ID: 16061849 [TBL] [Abstract][Full Text] [Related]
11. Expression and amplification of eIF-5A2 in human epithelial ovarian tumors and overexpression of EIF-5A2 is a new independent predictor of outcome in patients with ovarian carcinoma. Yang GF; Xie D; Liu JH; Luo JH; Li LJ; Hua WF; Wu HM; Kung HF; Zeng YX; Guan XY Gynecol Oncol; 2009 Feb; 112(2):314-8. PubMed ID: 19054548 [TBL] [Abstract][Full Text] [Related]
12. Histologically benign or low-grade malignant tumors adjacent to high-grade ovarian carcinomas contain molecular characteristics of high-grade carcinomas. Zheng J; Wan M; Zweizig S; Velicescu M; Yu MC; Dubeau L Cancer Res; 1993 Sep; 53(18):4138-42. PubMed ID: 8364906 [TBL] [Abstract][Full Text] [Related]
13. Analysis of telomerase activity in ovarian cystadenomas, low-malignant-potential tumors, and invasive carcinomas. Datar RH; Naritoku WY; Li P; Tsao-Wei D; Groshen S; Taylor CR; Imam SA Gynecol Oncol; 1999 Sep; 74(3):338-45. PubMed ID: 10479490 [TBL] [Abstract][Full Text] [Related]
14. Dynamic alterations of the extracellular environment of ovarian surface epithelial cells in premalignant transformation, tumorigenicity, and metastasis. Capo-Chichi CD; Smith ER; Yang DH; Roland IH; Vanderveer L; Cohen C; Hamilton TC; Godwin AK; Xu XX Cancer; 2002 Oct; 95(8):1802-15. PubMed ID: 12365030 [TBL] [Abstract][Full Text] [Related]
15. [P53-status in primary ovarian carcinomas, ovarian metastases of neoplasms in other sites and benign ovarian tumors: predictive value in comparison to histopathological parameters]. Casper F; Weikel W; Schaffrath M; Kuner RP; Hoffmann G; Pollow B; Pollow K Zentralbl Gynakol; 2000; 122(3):153-9. PubMed ID: 10756599 [TBL] [Abstract][Full Text] [Related]
16. [Expression and significance of tumor suppressor gene WAF1 in epithelial ovarian neoplasms]. Cao L; Yang Z; Li X Hunan Yi Ke Da Xue Xue Bao; 1998; 23(6):602-4. PubMed ID: 10806783 [TBL] [Abstract][Full Text] [Related]
17. Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei. McKenney JK; Soslow RA; Longacre TA Am J Surg Pathol; 2008 May; 32(5):645-55. PubMed ID: 18344868 [TBL] [Abstract][Full Text] [Related]
18. Expression of extracellular matrix proteins in ovarian serous tumors. Salani R; Neuberger I; Kurman RJ; Bristow RE; Chang HW; Wang TL; Shih IeM Int J Gynecol Pathol; 2007 Apr; 26(2):141-6. PubMed ID: 17413980 [TBL] [Abstract][Full Text] [Related]
19. CAS (cellular apoptosis susceptibility) gene expression in ovarian carcinoma: Correlation with 20q13.2 copy number and cyclin D1, p53, and Rb protein expression. Peiró G; Diebold J; Löhrs U Am J Clin Pathol; 2002 Dec; 118(6):922-9. PubMed ID: 12472286 [TBL] [Abstract][Full Text] [Related]
20. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas]. Shao HL; Shen DH; Xue WC; Li Y; Yu YZ Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]